Ocugen
Clinical trials sponsored by Ocugen, explained in plain language.
Biotech developing gene therapies and vaccines for eye diseases and COVID-19.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy slows vision loss in stargardt disease trial Results expected Sep 2026 (estimated) May already have reported ↗ 🚀 Make-or-break
- Gene therapy trial aims to restore night vision in rare eye disease Results expected Feb 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
- Can a single eye injection restore sight in genetic blindness? Results expected Mar 2027 (estimated)
-
Can a single eye injection restore sight in genetic blindness?
Cure OngoingThis trial tests an experimental gene therapy called OCU400 in people with retinitis pigmentosa or Leber congenital amaurosis, which are inherited conditions that cause progressive vision loss and can lead to blindness. The therapy is given as a single injection into the eye, wit…
Phase 1/2 • Sponsor: Ocugen • Aim: Cure
Last updated Aug 02, 2026 00:00 UTC
-
Gene therapy trial aims to restore night vision in rare eye disease
Disease control OngoingThis study tests a gene therapy called OCU400 for people with retinitis pigmentosa, an inherited eye disease that causes vision loss. The treatment is injected under the retina to help light-sensitive cells work better. The trial enrolled 140 people aged 3 and older and measures …
Phase 3 • Sponsor: Ocugen • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Gene therapy trial aims to halt blindness in dry AMD
Disease control OngoingThis study tests a gene therapy called OCU410 for geographic atrophy, a severe form of dry age-related macular degeneration that causes vision loss. About 60 adults aged 50 and older will receive a single injection of OCU410 into the eye. Researchers will monitor safety and check…
Phase 1/2 • Sponsor: Ocugen • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Gene therapy slows vision loss in stargardt disease trial
Disease control OngoingThis study tests a new gene therapy called OCU410ST for people with Stargardt disease, an inherited eye condition that causes vision loss. Early results show the treatment slowed damage to the retina by nearly half and improved or stabilized eyesight in all treated patients. The …
Phase 2/3 • Sponsor: Ocugen • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC